Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that market penetration of drugs that have been newly labeled to treat neuropathic pain, including Pfizer's Lyrica and Eli Lilly's Cymbalta will be a key driver of growth in the chronic pain drug market through 2016.
The new Pharmacor report entitled Chronic Pain finds that, following recovery from the withdrawals in 2004 and 2005 of two COX-2 inhibitors, the chronic pain market will regain momentum over the next decade, with 5 to 6% annual growth in total sales in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
"In contrast to older established drugs like amitriptyline, new agents such as Lyrica and Cymbalta have the safety and efficacy data from large-scale clinical trials that will allow them to compete in this market," said Kate Hohenberg, director at Decision Resources. "Both of these drugs will achieve blockbuster status in the chronic pain drug market by 2011 and sales of Lyrica will exceed $2 billion by 2016."
The chronic pain drug market in Japan will be particularly robust from 2011 to 2016 as drugs that include Cymbalta, Lyrica and Endo's Lidoderm reach that market. Also driving growth in Japan will be Pfizer's Celebrex which reached the Japanese market in 2007. The report also finds that the continued use of opioid analgesics for chronic, non-cancer pain and the introduction of more-tolerable, safer opioid formulations in the next five years will drive opioid analgesic sales for chronic pain to more than $6 billion by 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
About Chronic Pain
Key chronic pain populations, which account for approximately 80% of the drug market for chronic pain therapies and are covered in the report, include arthritic pain, chronic low back pain, fibromyalgia, diabetic neuropathic pain, postherpetic neuralgia, HIV-related neuropathic pain, chronic headache (including transformed migraine) and cancer pain. Sales of drugs to treat these and other, less clearly defined chronic pain conditions exceeded $14 billion in 2006 in the world's major pharmaceutical markets.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 firstname.lastname@example.org
First Call Analyst:
SOURCE: Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/